RETRACTED: MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway

Abstract

Background: MicroRNAs (miRNAs) are involved in oncogenesis of esophageal squamous cell carcinoma (ESCC). miR-134 is reported to have a tumour-suppressive role but its role in ESCC is not known. The present study was designed to examine whether miR-134 inhibits ESCC development and further explored relevant underlying mechanisms. Methods: Differentially expressed genes related to ESCC were identified from microarray gene expression profiles. Immunohistochemical staining and RT-qRCR assays identified elevated PLXNA1 expression levels and low miR-134. The relationship between miR-134 and PLXNA1 was predicted and further verified by a dualluciferase reporter assay. The expression levels of miR-134 and PLXNA1 in ESCC cells were modified by miR-134 mimic/inhibitor and siRNA against PLXNA1, respectively. Thereafter, the expression of MAPK signalling pathway-related proteins, as well as the viability, migration, invasion, cell cycle and cell apoptosis of ESCC cells was investigated. Findings: The results showed that miR-134 could block the MAPK signalling pathway by downregulating PLXNA1. When miR-134 was overexpressed or PLXNA1 was silenced, cell apoptosis was enhanced, the cell cycle was retarded, and the cell proliferation, migration and invasion were suppressed. In vivo experiments confirmed that miR-134 overexpression or PLXNA1 silencing restrained tumour growth and lymph node metastasis. Interpretation: These findings demonstrate that cancer cell proliferation, migration, invasion, and tumour metastasis of ESCC can be suppressed by overexpression of miR-134 through downregulating PLXNA1, which subsequently blocks the MAPK signalling pathway. These results provide new potential targets and strategies for the treatment of ESCC.

Circular RNA hsa_circ_0000654 promotes esophageal squamous cell carcinoma progression by regulating the miR‐149‐5p/IL‐6/STAT3 pathway

“…Similarly, miRNAs also play a significant regulatory role in ESCC. For instance, miR‐134 can restrain ESCC progression via downregulating PLXNA1 to block the MAPK signaling pathway . MiR‐488‐3p negatively modulates ZBTB2 and activates the p53 pathway to exert its anti‐cancer effect in ESCC .…”

“…For instance, miR-134 can restrain ESCC progression via downregulating PLXNA1 to block the MAPK signaling pathway. 17 MiR-488-3p negatively modulates ZBTB2 and activates the p53 pathway to exert its anti-cancer effect in ESCC. 18 Additionally, miR-149-5p is downregulated in multiple tumors, such as gastric cancer, non-small cell lung cancer, and osteosarcoma.…”

SNP Mutation‐related Genes in Colon Cancer for Monitoring and Prognosis of Patients: A Study Based on the TCGA Database

“…Relevant reports have shown that gene PLXNA1, which is signi cantly co-expressed with gene SPTBN2, is involved in the MAPK pathway. Silencing the expression of gene A can enhance cell apoptosis in esophageal squamous cell carcinoma, block cell cycle, inhibit cell growth, removal, and invade (32).Immunoin ltration analysis showed that the expressions of DAPK1 and DMXL2 DAPK1 and DMXL2 are likely to play an signi cant role in the research of immune cell in ltration and is a biomarker for the prognosis of patients with colon cancer.…”

Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma

“…Esophageal cancer (EC) is one of the most common gastrointestinal malignancies and ranks as the sixth most important cause of cancer mortalities globally, with an estimated 509,000 new deaths every year (1,2). As one of the most common histologic subtypes of EC, ESCC usually composes over 90% of all EC cases in parts of Asia and Sub-Saharan Africa (1,3). Although remarkable advances in surgical treatments, chemotherapy, and radiotherapy for ESCC, the 5-year overall survival rate is still <20%, due to the high incidences of tumor metastasis (4,5).…”